Plozasiran (Redemplo)

Key Messages

• Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses plozasiran injection (Redemplo), 25 mg/0.5 mL, sterile solution for subcutaneous use.
• Indication: As an adjunct to diet to reduce triglyceride levels for adult patients with FCS for whom standard triglyceride-lowering therapies have been inadequate.